TIS can be exploited for therapeutic purposes using "immunosenolytic" strategies, including adoptive cellular therapies such as chimeric antigen receptor (CAR)-engineered T and natural killer (NK) cells.
First-pass extracted concept
CAR-T/NK immunosenolytic therapy
Candidate: concept label1 source documents3 linked claims
Live refresh every 5sNext refresh in 5s
Aliases
adoptive CAR-T/NK immunotherapy, CAR-engineered T and natural killer (NK) cells
Evidence Snippets
Supporting Sources
Linked Claims
Mitochondrial apoptotic priming in target therapy-induced senescent cancer cells may limit the success of CAR-T/NK living drugs.
Quoted textsource-backed
A frequently overlooked barrier may limit the success of these living drugs: mitochondrial apoptotic priming in the target TIS cancer cells.
BH3 profiling could personalize CAR-based immunosenolytic therapy according to apoptotic readiness across pre- and post-therapy-induced senescence states.
Quoted textsource-backed
BH3 profiling could help to personalize CAR-based immunosenolytic therapy according to apoptotic readiness across pre- and post-TIS states.
Therapy-induced senescence can be therapeutically exploited using immunosenolytic strategies including CAR-engineered T cells and NK cells.
Quoted textsource-backed
TIS can be exploited for therapeutic purposes using "immunosenolytic" strategies, including adoptive cellular therapies such as chimeric antigen receptor (CAR)-engineered T and natural killer (NK) cells.